Cancer treatment-related cardiotoxicity is a leading cause of treatment-associated morbidity and mortality in cancer survivors. The gaps in knowledge related to cardiotoxicity are large, including mechanisms of cardiac injury, clinical risk prediction, screening, prevention, and treatment, as well as the similarities and differences between cancer induced cardiotoxicity and primary cardiovascular disease. This webinar – co-sponsored by the National Cancer Institute (NCI) and the National Heart, Lung, and Blood Institute (NHLBI) – will highlight the contributions of the NIH Cancer Treatment-related Cardiotoxicity Initiative to addressing gaps and on-going efforts to support cardio-oncology research.
Bishow Adhikari, Ph.D. - NHLBI, Division of Cardiovascular Sciences
Patrice Desvigne-Nickens, M.D. - NHLBI, Division of Cardiovascular Sciences
Eileen Dimond, R.N., M.S. - NCI, Division of Cancer Prevention
Lori Minasian, M.D., F.A.C.P. - NCI, Division of Cancer Prevention
Nonniekaye Shelburne, C.R.N.P., M.S., A.O.C.N. - NCI, Division of Cancer Control and Population Sciences
Scarlet Shi, Ph.D. - NHLBI, Division of Cardiovascular Sciences
Denise Wiesch, M.P.H., Ph.D. - NIH Center for Scientific Review